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Abstract: The occurrence of TERT promoter mutations has been well described in soft tissue sarcomas
(STS). However, the biological role of these mutations as well as their impact on telomere length
in STS is still unclear. We analyzed 116 patient samples diagnosed with 22 distinct histological
subtypes of bone and STS for the occurrence of TERT promoter mutations by Sanger sequencing.
We observed TERT promoter mutations at an overall frequency of 9.5% distributed over 7 different
sarcoma subtypes. Except for one chondrosarcoma case harboring a C250T mutation, all other
mutations were detected at location C228T. By far the far highest frequency of TERT promoter
mutations was found in myxoid liposarcoma (MLS) (4 out of 9 cases studied, i.e., 44%). Assessment
of telomere length from tumor biopsies revealed that TERT promoter-mutated MLSs had significantly
fewer shortened telomeres in comparison to TERT wildtype MLSs. Based on the frequency of TERT
promoter mutations and the elongated telomere length in mutated compared to wildtype MLS, we
hypothesize that occurrence of TERT promoter mutations has a pivotal role in the disease progression
as a secondary genetic event at a time when tumor cells face the need for telomere elongation to allow
further proliferation.
Keywords: myxoid liposarcoma; sarcoma; telomere; telomerase; TERT promoter mutation
1. Introduction
Telomeres are repetitive DNA sequences protecting the ends of chromosomes. Telomeres shorten
with each cell division, and telomere length (TL) limits the replicative capacity of a cell once telomeres
become critically short [1,2]. Telomere shortening can be counteracted by the expression of telomerase
(TERT), an enzyme that can (re-)elongate telomeres [3,4] a phenomenon that can also be used
therapeutically in vivo [5]. One of the hallmarks of cancer is unlimited cell division [6]. Previous studies
showed that tumor cells mostly maintain their telomere length by increased telomerase expression [7]
and rarely by a mechanism called alternative lengthening of telomere (ALT) [8]. However, the exact
mechanism how tumor cells increase telomerase activity is incompletely understood and varies
between the different tumor entities [9].
Recently, two highly recurrent mutations in the promoter region of TERT (c.-124 C>T and c.-146
C>T), also called C228T and C250T, respectively were described in 71% of all melanomas [10,11].
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In follow up studies, these mutations were reported to be, overall, the most prevalent somatic point
mutations being present at varying frequencies in over 50 different types of cancers [12–16]. Of note,
both the C228T and the C250T mutation are typically heterozygous, mutually exclusive, and both
create the identical 11bp sequence (i.e., “CCCGGAAGGGG”) that has substantial similarity to an ETS
binding motif representing a de-novo binding site for an activating ETS family transcription factor.
Both mutations activate TERT promoter activity and TERT gene transcription functionally resulting in
in vitro telomere elongation [10,11].
Soft tissue sarcomas (STS) represent a heterogeneous disease with more than 50 clinically
relevant subtypes with different histologies, molecular-genetic profiles, tumor-location patterns,
and prognoses [17–19]. Genomic alterations including chromosomal translocations, DNA copy
number variations and the presence of typical genetic aberrations are hallmarks of certain subtypes
of sarcomas [20]. One of the molecularly best-studied subtypes is myxoid liposarcoma (MLS).
In 95% of the cases, MLSs share the reciprocal translocation t(12;16)(q13; p11). The breakpoint on
chromosome 12 involves the transcription factor CHOP (C/EBP homologous protein), member of the
CAAT/enhancer-binding protein (C/EBP) family, a gene involved in adipocyte differentiation [21,22].
The CHOP protein presents a leucine zipper dimerization domain that can bind C/EBP proteins and
block the interaction with DNA [21,22]. The breakpoint on chromosome 16 involves the FUS/TLS
(Fused in Sarcoma/Translocated in Sarcoma) gene, an RNA-binding protein and member of the
TET protein family that also includes the EWS protein. The main characteristic of this chromosomal
translocation is that it results in the expression of the fusion transcript TLS/FUS-CHOP. Functionally,
the resulting FUS-DDIT3 fusion protein induces increased expression of the C/EBP promoting
oncogenic activation and tumor formation [23–25]. Based on the oncogenic potential and respective
mouse models [26], the occurrence of t(12;16)(q13; p11) translocation is generally expected to be the
first event in sarcoma initiation in MLS.
In the literature, only a few studies exist on telomeres or TERT promoter mutation status in
sarcoma. These include the introduction of telomere length as a prognosis marker in Ewig sarcoma [27],
the association of telomere length of peripheral blood leukocytes with increased risk for soft tissue
sarcoma [28], telomere length in complex and simple karyotype sarcomas [29], assessment of ALT
in sarcoma [30–34], mosaicism of telomere maintenance mechanisms in sarcomas [35,36] and the
frequency of TERT promoter mutations in sarcomas [13,37–39]. However, no study has so far correlated
TERT promoter status and telomere length in bone and STSs.
The aim of our study was first to investigate the prevalence of TERT promoter mutations in the
different sarcoma subtypes and second to analyze the relation between presence of TERT promoter
mutations and telomere lengths in a specific subtype of sarcomas, the MLSs.
2. Results
2.1. TERT Promoter Mutations in Bone and Soft Tissue Sarcomas (STS)
First, we analyzed for the incidence of TERT promoter mutations in 116 bone and STS tumors of
22 different subtypes (Table 1). We found mutations in 11/116 patients (9.5%), namely in four cases of
MLS, one solitary fibrous tumor (SFT), two malignant fibrous histiocytomas (MFH) or undifferentiated
pleomorphic sarcoma (UPS), one pleomorphic sarcoma, one poorly differentiated sarcoma NOS and
two chondrosarcomas (Figure 1; Table 2). Of note, 10 out of 11 (91%) mutations found were C228T and
only in one patient with chondrosarcoma we observed a TERT promoter mutation at position C250T
(Table 3). In Table 1, mutation frequencies are summarized in a side-by-side comparison with different
studies reported in the literature.
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Figure 1. Representative chromatograms of heterozygous TERT promoter mutations in two bone and 
soft tissue sarcomas. Sequencing direction: (A) sense, (B) antisense. An arrow indicates mutations. 
Table 1. Overview of the frequency of TERT promoter mutations in soft tissue and bone sarcomas 




(n = 116) 
22 Subtypes 
Saito 2016 








(n = 341) 
16 Subtypes 
Killela 2013 
(n = 95) 
6 Subtypes 
Soft tissue sarcomas 
WDLS 0/5 (0%) 0/18 (0%) 0/1 (0%) NA NA 
Myxoid liposarcoma 4/9 (44%) 3/13 (23%) 2/9 (22.2%) 29/39 (74%) 
19/24 
(79.1%) 
Pleomorphic liposarcoma 1/4 (25%) NA 1/1 (100%) 0/15 (0%) NA 
Dedifferentiated 
liposarcoma 
0/12 (0%) NA 1/1 (100%) 0/61 (0%) NA 
Liposarcoma 0/7 (0%) NA NA NA NA 
Leiomyosarcoma 0/9 (0%) 0/24 (0%) 0/13 (0%) 0/27 (0%) NA 
Cytosarcoma Phyllodes 0/1 (0%) NA NA NA NA 
Angiosarcoma 0/3 (0%) NA NA 0/9 (0%) NA 
Rabdomyosarcoma 0/8 (0%) 0/5 (0%) NA NA NA 
Haemangiosarcoma 0/1 (0%) NA NA NA NA 
MPNST 0/8 (0%) 0/1 (0%) 0/7 (0%) 2/35 (6%) NA 
UPS (previous MFH) 2/9 (22.2%) 1/22 (4.5%) 0/12 (0%) 0/40 (0%) NA 
Fibrosarcoma NA NA 0/1 (0%) NA 1/3 (33.3%) 
Myofibroblastic sarcoma 0/3 (0%) NA 0/3 (0%) NA NA 
Myxofibrosarcoma 0/1 (0%) 0/6 (0%) 0/5 (0%) 0/17 (0%) 1/10 (10%) 
NOS 0/11 (0%) NA NA NA NA 
NOS, poorly differentiated 1/8 (12.5%) NA NA NA NA 
Clear cell sarcoma 0/1 (0%) 0/1 (0%) 0/1 (0%) 0/5 (0%) NA 
Synovial sarcoma 0/9 (0%) 0/7 (0%) 0/9 (0%) 1/25 (4%) NA 
Ewing sarcoma 0/1 (0%) 0/6 (0%) NA NA NA 
SFT 1/1 (100%) 5/40 (12.5%) 0/1 (0%) 4/31 (13%) 2/10 (20%) 
Bone sarcomas 
Chondrosarcoma 2/8 (25%) 0/10 (0%) NA 0/8 (0%) 1/2 (50%) 









NA—not available; WDS—well-differentiated liposarcoma; UPS—undifferentiated pleomorphic 
sarcoma; MPNST—malignant peripheral nerve sheath tumor; SFT—solitary fibrous tumor; MFH—
malignant fibrous histiocytoma; NOS—not otherwise specified; UPS—undifferentiated pleomorphic 
sarcoma. 
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WDLS 0/5 (0%) 0/18 (0%) 0/1 (0%) NA NA
Myxoid liposarcoma 4/9 (44%) 3/13 (23%) 2/9 (22.2%) 29/39 (74%) 19/24 (79.1%)
Pleomorphic liposarcoma 1/4 (25%) NA 1/1 (100%) 0/15 (0%) NA
Dedifferentiated
liposarcoma 0/12 (0%) NA 1/1 (100%) 0/61 (0%) NA
Liposarcoma 0/7 (0%) NA NA NA
Leiomyosarcoma 0/9 (0%) 0/24 (0%) 0/13 (0%) 0/27 (0%) NA
Cytosarcoma Phyllodes 0/1 (0%) NA NA NA NA
Angiosarcoma 0/3 (0%) NA NA 0/9 (0%)
Rabdomyosarcoma 0/8 (0%) 0/5 (0%) NA NA
Haemangiosarcoma 0/1 (0%) NA NA NA NA
MPNST 0/8 (0%) 0/1 (0%) 0/7 (0%) 2/35 (6%) NA
UPS (previous MFH) 2/9 (22.2%) 1/22 (4.5%) 0/12 (0%) 0/40 (0%) NA
Fibrosarcoma NA NA 0/1 (0%) NA 1/3 (33.3%)
Myofibroblastic sarcoma 0/3 (0%) NA 0/3 (0%) NA
Myxofibrosarcoma 0/1 (0%) 0 6 (0%) 0/5 (0%) 0/17 (0%) 1/10 (10%)
NOS 0/11 (0%) NA NA NA NA
NOS, poorly differentiated 1/8 (12.5%) NA NA NA NA
Clear cell sarcoma 0/1 (0%) 0/1 (0%) 0/1 (0%) 0/5 (0%) NA
Synovial sarcoma 0/9 (0%) 0/7 (0%) 0/9 (0%) 1/25 (4%) NA
Ewing sarcoma 0/1 (0%) 0/6 (0%) NA NA
SFT 1/1 (100%) 5/40 (12.5%) 0/1 (0%) 4/31 (13%) 2/10 (20%)
Bone sarcomas
Chondrosarcoma 2/8 (25%) 0/10 (0%) NA 0/8 (0%) 1/2 (50%)
Osteosarcoma 0/3 (0%) 0/14 (0%) NA NA 1/23 (4.3%)
Overall 11/ 16 9.5%) 9/167 5.4%) 4/68 (5.9 ) 36/341 (10.5%) 25 72 (34.7%)
NA—not available; WDS—well-differentiated lipos rcoma; UPS—undifferentiated pleomorphic sarcoma;
MPNST—malignant peripheral nerve sheath tumor; SFT—solitary fibrous tumor; MFH—malignant fibrous
histiocytoma; NOS—not otherwise specified; UPS—undifferentiated pleomorphic sarcoma.
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Table 2. Clinical characteristics of the selected cohort of soft tissue and bone sarcoma patients.






































N—number of cases. Tumor location “Others” included bladder, ear, gluteus, groin, liver, maxilla, nose,
paravertebral, parotis, pleural, prostate, renal, rip/sternum, shoulder, skin, Vena cava. NA—not available. Disease
progression during follow-up. Metastasis during follow-up.
2.2. Tumor Grading Correlates with the Presence of TERT Promoter Mutations
We next focused on whether the presence of TERT promoter mutations correlated with clinical
features of our sarcoma cohorts. We did not observe any significant differences comparing the initial
tumor localization: head/neck 10% (1/10), extremities and superficial trunk 18% (5/27), retroperitoneal
0% (0/18), abdomino-thoracic 4% (1/24) or others 13% (4/30). Since the histological grading is
one of the most important factors for clinical decision-making, we compared patients according to
histological grading. Patients with histopathological G1 grading/well-differentiated tumors showed
significant higher percentage of TERT promoter mutations (5/21, 24%) compared to patients with
G2-3 grading/poor differentiation (6/92, 7%, p = 0.030, see Table 2). No further clinical characteristics
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such as age, gender, race, disease progression status or development of metastasis (Table 2) differed
significantly among WT and TERT promoter-mutated patients.
Table 3. Details of TERT promoter (TERTp) mutated-patients.
Diagnosis Age/Gender Location TERTp Mutation Tumor Grade Metastasis Progression
MLS 61/F thigh C228T G1 NA NA
MLS 71/M femoral C228T G1 yes yes
MLS 23/M lung C228T G1 NA NA
MLS 43/F spine C228T G2 yes yes
PS 58/F femoral C228T G2 no no
MFH 68/M skin C228T G2 no no
MFH 78/M hip C228T G3 yes no
CS 37/M femoral C228T G2 no no
CS 46/F jaw C250T G1 no no
SFT 64/F NA C228T well diff. yes yes
NOS 68/M ear C228T G2 no no
Age given in years. MLS—myxoid liposarcoma; PS—pleomorphic sarcoma; MFH—malignant fibrous histiocytoma;
CS—chondrosarcoma; SFT—solitary fibrous tumor; NOS—not otherwise specified; NA—not available; well
diff.—well-differentiated tumor. Metastasis and disease progression during follow-up.
2.3. Myxoid Liposarcomas (MLSs) Exhibit Longer Telomeres than Wildtype Tumors
Next, we focused on MLS based on the incidence of TERT promoter mutations—ranging in the
literature from 22% to 79% (Table 1)—as well as their homogenous genetic background characterized by
the translocation t(12;16)(q13; p11), a genetic hallmark of MLS. Among the wildtype tumors, MLS only
one (1/5 = 20%) presented distant metastasis in contrast to 2 out of 2 (100%) TERT promoter-mutated
tumors from which patient clinical data was available.
Since telomere length declines with age, the comparison of the age of the patients did not reveal
significant differences between MLS wildtype (61.4 ± 6.0 years, n = 5) and TERT promoter-mutated
tumors (49.5 ± 10.6 years, n = 4; p = 0.33). Interestingly, telomere length of MLS samples with TERT
promoter mutations was found to be significantly less shortened (8.10 ± 0.50 kb; n = 4) compared to
the telomere length of wildtype tumors (6.61 ± 1.06 kb; n = 5; p < 0.037) (Figure 2A–C). No statistically
significant correlations between elongated telomere length and age, gender, tumor location, tumor
grade, disease progression, and development of metastasis were observed likely due to small sample
size. Assessment of ALT revealed no evidence of significant heterogeneity of telomere sizes, which
would reveal the presence of ALT, in either TERT promoter MLS or wiltype tumors (Figure S1).
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Figure 2. Representative Q-FISH images captured by confocal laser scanning microscopy: (A) C228T 
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liposarcoma patient. Magnification 630×. (C) Quantification of telomere length after Q-FISH analysis 
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mutations in G1 tumors than in G2–3 tumors. The high frequency of TERT promoter mutations in 
just two nucleotide positions strongly suggests a possible role as drivers, i.e., primary or secondary 
events in tumor pathogenesis [12]. Chiba et al. have indeed shown that TERT promoter mutations 
are sufficient to overcome the proliferative barrier imposed by critical telomere shortening without 
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mutations are among the earliest genetic events in bladder cancer [41], thyroid carcinoma [42], 
cutaneous melanoma [14,43,44], basal cell and squamous cell carcinoma [45] and oligodendroglioma 
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secondary genetic event following the activation of an oncogenic signaling pathway, such as MAPK 
signaling in melanoma [14] or Wnt signaling in hepatocellular carcinoma [47]. 
Based on these observations, we aimed to analyze the impact of the TERT promoter mutations 
on telomere lengths. Therefore, we used MLS as an ideal model to study telomere lenght in sarcoma 
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3. Discussion
Our study introduces the third largest cohort of bone and STS analyzed for TERT promoter
mutations among literature [37,38] and the first systematic analysis of telomere length in TERT
promoter-mutated MLS. We report the prevalence of TERT promoter mutations (overall incidence near
to 9.5%) to vary widely among different bone and STS subtypes (ranging from 0–44%), with the highest
mutation frequency found within MLS subgroup (44% harboring a C228T mutation at the promoter
region of the TERT gene). The two existing mutations C228T and C250T were found to be mutually
exclusive in every case. Our results add value to previous studies on smaller cohorts or limited number
of sarcoma subtypes, as those same hotspot mutations have also previously been characterized
as recurrent in MLS but rather uncommon in other subtypes (Table 1) [13,37–39]. However,
the mutational frequency in the MLS subgroup appears to fluctuate substantially among studies
(22–23% vs. 40% vs. 74–79%) apparently due to differences in the size of the cohorts (Table 1) [13,37–39].
Of note, the C228T is the predominant mutation found in our sarcoma cohort similar to the results
of previous studies [13,37–39]. Yet, we describe the first case of a C250T TERT promoter mutation in
a chondrosarcoma, after Killela et al. [13] who reported the other known published case.
TERT promoter mutations occur mainly in tumors that are derived from tissues with low rates
of self-renewal [13,14]. In line with this observation, we found significant more TERT promoter
mutations in G1 tumors than in G2–3 tumors. The high frequency of TERT promoter mutations in
just two nucleotide positions strongly suggests a possible role as drivers, i.e., primary or secondary
events in tumor pathogenesis [12]. Chiba et al. have indeed shown that TERT promoter mutations
are sufficient to overcome the proliferative barrier imposed by critical telomere shortening without
additional tumor-selected mutations [40]. In addition, some studies suggest TERT promoter mutations
are among the earliest genetic events in bladder cancer [41], thyroid carcinoma [42], cutaneous
melanoma [14,43,44], basal cell and squamous cell carcinoma [45] and oligodendroglioma [46].
In contrast, other studies implicate that the occurrence of TERT mutations is more likely a secondary
genetic event following the activation of an oncogenic signaling pathway, such as MAPK signaling in
melanoma [14] or Wnt signaling in hepatocellular carcinoma [47].
Based on these observations, we aimed to analyze the impact of the TERT promoter mutations on
telomere lengths. Therefore, we used MLS as an ideal model to study telomere lenght in sarcoma as
this sarcoma subtype is not only characterized by a typical initial oncogenic driver translocation, i.e.,
the t(12;16)(q13; p11) [26,48], but also by a substantially higher incidence of TERT promoter mutations
Int. J. Mol. Sci. 2018, 19, 608 7 of 13
compared to other sarcomas subtypes [13,37–39]. Our telomere analysis on MLS histopathological
slides revealed significantly less shortened telomeres in MLS with TERT promoter mutations compared
to wildtype tumors after age matching. Of note, the telomere length of wildtype tumor was close to
the range where telomeres become critically short (known to be near 3–5 kb [49–52]) as e.g., similar
to the telomere length of patients with dyskeratosis congenita, a disease characterized by mutations
within the telomerase complex [53]. In line with our telomere data, Kabjorn et al. found that MLS
typically display a major population of senescent cells [54]. It is tempting to speculate that in some
of the cases described critically short telomeres might contribute to cell senescene due to unresolved
telomere crisis.
One explanation for our observations might be the upregulation of telomerase activity by
frequently occurring TERT promoter mutations leading to telomere elongation/maintenance in TERT
promoter-mutated tumors. Due to poor quality of the RNA extracted from older paraffin embedded
tumor samples in our patient cohort, analysis of TERT expression and/or telomerase activity is
extremely limited to further support our hypothesis. Other mechanisms for telomere elongation as
e.g., ALT do not play an important role in our patient cohort, in line with the observed low frequency
(approx. 5–13%) estimated by other studies [33,34]. No data is available with regard to the possibility
of increased expression of C/EBP—due to FUS-DDIT3—increasing TERT expression in tumor cells.
However, the high incidence of TERT promoter mutations in MLS implies that C/EBP has no major
role in telomerase regulation and telomere maintenance.
Alternatively, TERT promoter mutations preferentially occur in tumor cells with longer telomeres
or occur before the typical initial oncogenic driver translocation. The latter seems less likely due
to substantially higher incidence of oncogenic driver as opposed to (presumably secondary) TERT
promoter mutations. To clarify this issue, telomere length and TERT promoter status of the tissue from
where MLS originates should be analyzed. However, the cell-of-origin in MLS sarcomas, most likely
transformed mesenchymal stem cells and/or their immediate lineage progenitors [55,56], remains
unknown, thus limiting definitive conclusions.
Based on our experimental data, we propose that the acquisition of TERT promoter mutations is
a secondary event in disease progression of MLS required to protect MLS cells from growth arrest due
to replication-induced critically short telomeres (see proposed model in Figure S2)
Although is it evident that TERT promoter mutation status and telomere regulation is variable
and complex among different cancers types, particularly due to the variety related to tumor cell
origin, tumor subtype [29–39,57], our proposed model is further substantiated by others studies.
In follicular and atypical thyroid adenoma [42] as well as gliomas, TERT promoter mutations lead
to significantly increased telomerase activity [12,13,58] explaining longer telomeres observed in our
cohort of mutated MLS. Similarly, in bladder cancer it has been shown that TERT promoter mutations
promote a mechanism for high-level telomerase reactivation associated with stable telomere length [59].
TERT promoter mutations alone have been linked with worse prognosis in various tumor
entities such as melanoma [60,61], glioblastoma multiforme [13], medulloblastoma [62], urogenital
cancer [63,64], laryngeal tumors [65], and with larger tumors and lymph node metastasis in the case of
conventional papillary thyroid carcinomas [12,66–68]. Unfortunately, the low number of MLS cases
in our study did not allow correlations with clinical outcome. Based on the role of TERT promoter
mutations in other tumor entities and the perception that its occurrence is a secondary event in MLS,
it is tempting to see clinical similarities between MLS and e.g., gliomas [69]. However, further studies
are needed to unravel the role of TERT promoter mutations in MLS.
In summary, we observed that in a subset of MLS patients, TERT promoter mutations likely
occur as a secondary event in a setting of critically short telomere length, most likely reflecting
a compensatory mechanism that allows telomeres to elongate/maintain. Further studies are needed to
further analyze the impact of TERT promoter mutations and telomere length on clinical outcome.
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4. Material and Methods
4.1. Sarcoma Samples
Formalin-fixed paraffin-embedded (FFPE) slices of 116 patients diagnosed between 2007 and 2014
with a large variety of histological subtypes of bone and STS were analyzed. Samples were obtained
from diagnostic or surgical resections from the archive of the Institute of Pathology of the University
Hospital RWTH Aachen. Informed consent for retention and analysis of the tissue for research
purposes was obtained from all patients (local ethical review board of the Medical Faculty of the
RWTH Aachen University, EK-206/09). In this study, the following sarcoma subtypes were included:
undifferentiated pleomorphic sarcoma (n = 9); dedifferentiated liposarcoma (n = 12); well differentiated
liposarcoma (n = 5); pleomorphic sarcoma (n = 4); liposarcoma (n = 7); MLS (n = 9); sarcoma not
otherwise specified (NOS, n = 11); synovial sarcoma (n = 9); chrondroma (n = 1); chondrosarcoma
(n = 9); osteosarcoma (n = 3); rhabdomyosarcoma (n = 8); leiomyosarcoma (n = 9); myofibroblastic
sarcoma (n = 3); myxofibrosarcoma (n = 1); malignat peripheral nerve sheath tumor (n = 8); solitary
fibrous tumor (n = 1); clear cell sarcoma (n = 1); Ewing sarcoma (n = 1); Cytosarcoma phyllodes (n = 1);
epitheloid haemangiosarcoma (n = 1); and angiosarcoma (n = 3). Tumors were staged according to
the TNM classification of malignant tumors (TNM) staging system of the Union for International
Cancer Control (UICC). Detailed clinical patient characteristics are summarized in Table 2. For TERT
promoter-mutated patients additional parameters are shown in Table 3.
4.2. Polymerase Chain Reaction (PCR) Amplification and Sanger Sequencing
One single 10 µm slice was prepared from each FFPE tumor block and used for extraction of
genomic DNA. Extraction was done using the GeneRead DNA FFPE kit (Qiagen, Germany), according
to the manufacturer’s instructions. The extracted DNA was quantified by spectrophotometry using
Nanodrop spectrophotometer (Thermo Fischer, Schwerte, Germany). The protocol for polymerase
chain reaction (PCR) amplification followed previously published protocols [10]. Briefly, 150 ng of
DNA template in a total volume of 50 µL were used, 2.5 U/reaction Taq Biotherm DNA polymerase
(Genecraft, Köln, Germany) were used and cycling conditions included initial denaturation at 94 ◦C
for 120 s, followed by 35 cycles with denaturation at 94 ◦C for 60 s, annealing at 60 ◦C for 30 s
and extension at 72 ◦C for 30 s. PCR primers amplifying a fragment of the hTERT promoter
region containing the sites of the c.-124 C>T (C228T) and c.-146 C>T (C250T) mutations were
used to screen for mutations. The primers hTERT-286-R: 5′-CTCCCAGTGGATTCGCGGGC-3′ and
hTERT-27-F: 5′-CCCACGTGCGCAGCAGGAC-3′, yielding a 260 bp product, were used for all
samples. When amplification of the larger fragment failed, the alternative primers hTERT-200-R:
5′-CACCCGTCCTGCCCCTTCACCTT-3′ and hTERT-26-F: 5′-GGCTTCCCACGTGCGCAGCAGGA-3,
yielding a 192 bp product, were used. A run 1.6% agarose gel was used to confirm the presence of
amplified products. PCR products were clean with the Clean & Concentrator Kit-5 (Zymo Research,
Irvine, KY, USA) before being sent to Eurofins Genomics (Ebersberg, Germany) for Sanger sequencing
analysis to confirm the presence/absence of mutations. Analysis of chromatograms and sequences
was performed with GENtle 2.0 software (open source).
4.3. Telomere Length Analysis by Quantitative In Situ Hybridization (Q-FISH)
For quantitative in situ hybridization (Q-FISH), 5-µm archive FFPE slices were prepared and
stained as previously published [49,70–73]. Deparaffinized and dehydrated sections were incubated
with a Cy3-(C3TA2)-PNA (Panagene, Daejeon, Korea) probe for 2 h before being washed and nuclei
counterstained using 0.1 µg/mL DAPI (Sigma, München, Germany). Stained slides were stored at
4 ◦C and laser confocal microscopy images captured within 72 h after sample processing. Telomere
signals were acquired with a Zeiss LSM710 (Jena, Germany) confocal laser-scanning microscope.
Images were captured at optical magnification of 63×, with additional 1.2× digital zoom under
multi-tracking mode with 1 µm steps (maximum intensity projections of 5 steps were prepared).
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Five tumorigenic areas (>100 cells total) were captured for each slice. Patients with or without
TERT promoter mutation were assessed in parallel. Telomere length was quantified using Definiens
Developer Software (Definiens 2.3, München, Germany). Nuclei and telomeres were detected based on
the respective DAPI and Cy3 intensities. Telomere length was calculated in kb using internal controls
as described previously [49,70–73].
4.4. Alternative Lengthening of Telomeres (ALT) Assessment
The presence of ALT phenotype was assessed by the identification of very large and bright
intranucelar foci of telomere FISH signals after Q-FISH staining. Criteria for ALT positivity was
≥1% tumor cells displaying ultra-bright intranuclear foci of telomere FISH signals with foci intesity
being 10-fold higher than mean intesity of all telomeric signals in non-tumor stroma cells wihtin each
sample [74]. A glioblastoma sample was included as positive control for the presence of ALT.
4.5. Statistical Analysis
GraphPad Prism 5.0 (GraphPad, La Jolla, CA, USA) was used for statistical analysis. Differences
in telomere length between the groups were evaluated by unpaired t-testing. Chi-square test was used
to compare patient’s characteristics between WT and TERT promoter-mutated groups. p < 0.05 was
statistically significant.
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